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Electrolytes in the ICU
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Abstract
Electrolyte disorders is an imbalance of certain ionized salts (sodium, potassium,
calcium, bicarbonate, chloride) in the blood. Healthcare providers should be famil-
iar with the principles of electrolyte physiology and pathophysiology. Disturbances
in sodium homeostasis are primarily caused by volume abnormalities leading to
primarily neurologic symptoms. Dyskalemias frequently present with cardiac man-
ifestations therefore should be treated promptly before evaluating its cause. Ion
deficiencies such as hypocalcemia, hypomagnesemia and hypophosphatemia should
be corrected as they are associated with increased adverse events in critically ill
patients.
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1. Introduction
Electrolytes are elements that naturally occur in the human body and help
balance pH, facilitate passage of fluid through osmosis and regulate the function of
neuromuscular, endocrine and excretory systems. Disturbances in these electrolytes
are common clinical problems encountered in the intensive care unit with serious
complications when they are depleted. Recent studies report that electrolyte imbal-
ances are associated with increased morbidity and mortality. Possible mechanisms
include damage to the kidney, activation of hormonal systems (such as RAAS) or
the myriad of medication given in a critically ill patient. This chapter will focus on
various electrolyte abnormalities seen in the critical care setting then touch on
important ICU scenarios which could affect electrolytes.
2. Disorders of sodium homeostasis
• Serum sodium reflects the plasma tonicity and is inversely related to total body
water. Changes in sodium are generally due to changes in total body water, not
serum sodium, which regulates plasma tonicity and effective arterial volume.
The body normally prevents plasma sodium to stray outside normal range (135
to 145 mEq/L or mmol/L) by controlling water intake and excretion.
• Sodium crosses systemic capillary membranes through clefts between
endothelial cells therefore sodium concentration is identical in plasma and
interstitial fluid [1]. Brain capillaries have tight endothelial junctions lined by
astrocytic foot processes creating the blood–brain barrier which sodium cannot
cross [2]. Consequently, an abnormal plasma sodium causes water movement
across the blood brain barrier leading to either brain swelling or shrinkage.
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• Osmoreceptors are hypothalamic neurons that are responsible for adjusting
thirst and vasopressin secretion based on plasma sodium. Vasopressin binds to
V2 receptors on the principal cells lining the renal collecting duct [3]. In the
presence of vasopressin, water is allowed to flow out of the collecting tubule in
the nephron attracted by a high solute concentration of the surrounding




• Hyponatremia is defined as serum sodium below 135 mEq/L (135 mmol/L). It is
the most common electrolyte disorder seen in clinical practice and the
consequences can range from minor symptoms to life threatening
complications including seizures and cardiorespiratory distress. 30% of
critically ill patients have serum sodium<134 mEq/L [4]. Patients with
hyponatremia are seven times more likely to die than those without
hyponatremia during hospitalization [5].
• Hyponatremia can be classified based on temporality (acute <48 hrs; chronic
>48 hrs) or based on serum sodium (mild 130-135 mEq/L (mmol/L); moderate
125-130 mEq/L (mmol/L); severe <125 mEq/L (mmol/L)) [6].
2.1.2 Presentation
• Patients with mild to moderate hyponatremia can present with nausea,
confusion, headaches whereas moderate to severe hyponatremia can
presenting with vomiting, cardiorespiratory distress, seizures and reduced
consciousness [6].
• Patients are likely to present with severe symptoms if they have acute onset
hyponatremia while chronic hyponatremia has a lower risk of neurological
dysfunction as the brains counter-regulatory mechanisms [7].
2.1.3 Diagnostic approach
• The diagnostic approach of hyponatremia should follow a logical progression,
answering several key questions. See Figure 1.
2.1.4 Treatment
• Treatment of hyponatremia is based on underlying pathogenesis.
• In patients who present symptomatically with hyponatremia, they should be
considered as an emergency and given hypertonic therapy. 3% normal saline
can be used, 150 ml over 20 min. Lab work should be obtained after hypertonic
therapy is administered and the goal is to increase sodium by 3-5 mM which
should improve patient’s symptoms. If patients symptoms persist and sodium
has increased by <4 mM then another round of hypertonic therapy can be
given. If sodium increased by >6 mM and symptoms have not resolved, then
further workup should be performed to check for alternative pathologies.
Hypertonic bicarbonate has the same tonicity as 6% NaCl and is usually
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the fastest medication to obtain in an emergency. Typical dose of two ampules
of hypertonic bicarbonate is equivalent to 200 ml of 3% saline [8]. See
Figure 2.
• Depending on the pathology, hyponatremia will be treated differently [9].
• In patients with ADH absent states, hyponatremia is caused because patient is
drinking more fluid than the kidney can handle. In primary polydipsia, fluid
restriction would be ideal [9].
• Normally the kidneys require solute to create urine therefore in patients with
poor nutritional status, a normal amount of water/alcohol will cause
hyponatremia. In patients with reduced dietary solute intake (such as chronic
alcoholics), instituting a proper diet will correct hyponatremia. These patients
can be given isotonic fluid is clinical evidence of hyponatremia [9].
• ADH absent states are high risk for over-correction therefore should be
monitored closely.




Normal diet contains 600-900 mosmol of solute/day and the minimum urine
osmolality is 60 mosmol/kg therefore the maximum urine output (see Eq. 1) in a
normal patient would be:
Maximum Urine Output ¼
900
60
¼ 15 litres per day
Therefore, in patients with primary polydipsia, they will overcome the maxi-
mum urine output while patients with reduced solute intake will have reduced
maximum urine output.
Figure 1.
Diagnostic approach to hyponatremia, starting with osmolality.
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• In patients who have reduced EABV, treating the primary pathology will
improve the serum sodium. History and physical examination is important when
it comes to this patient population to effectively start correct treatment plan.
• In SIADH, the underlying cause should be treated concomitantly with initial
treatment to raise serum sodium. Fluid restriction is the mainstay of therapy.
In patients who have chronic SIADH, sodium or urea tablets can be used. Since
patients with SIADH have a fixed urine osmolality, solute loads (such as urea
and sodium tablets) are used to increase maximum urine output by increasing
dietary solute [8, 9].
• In a patient who presents to the hospital with hyponatremia, it will be assumed
to be chronic in nature. The target goal for these patients is 6-8 mEq/L (mmol/
L) in a 24-hour period. Excessively rapid correction leads to osmotic
demyelination syndrome.
• Common causes of hyponatremia overcorrection are:
1.Treating the underlying cause
2.Potassium Supplementation
Figure 2.
Treatment algorithm for hyponatremia.
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3.Vaptans
• Risk factors for over-correction are cirrhosis, alcoholism, malnutrition and
hypokalemia.
• Administration of potassium will also increase plasma sodium because it enters
the cells, increasing intracellular osmolality and causing water to move from
the extracellular space into the intracellular space, thus raising plasma sodium
concentration
2.1.5 Overcorrection of sodium
• In a patient whose sodium was corrected outside 24 hour parameters can be
started on rescue strategy. Desmopressin can be given (dose: 2mcg IV/subQ
every 6 hours) to reduce free water output. Concomitantly, free water should
be given (D5W at 6 ml/kg infused over 2 hours with labs after every infusion to
determine rate of lowering) with the goal to bring sodium back within suitable
levels for the next 24 hours. Once the sodium goal is achieved, the D5W can be
stopped but desmopressin can be continued to prevent overly rapid correction
[8, 9].
• Osmotic Demyelination syndrome: This syndrome usually has a delayed
presentation 2-6 days after over-correction. Symptoms are dysarthria,
dysphagia, paresthesia, quadriparesis and seizures. These symptoms are
irreversible. MRI brain will show demyelinating lesions however may not
appear for atleast 4 weeks after disease onset. Earlier detection may be possible
with newer techniques such as DWI [8, 9].
2.2 Hypernatremia
2.2.1 Introduction
• Hypernatremia is defined as >145 mEq/L (mmol/L). This is often seen in
hospitalized patients and is associated with increased mortality in patients
[10–12]. Hypernatremia represents a deficit of water in relation to the body’s
sodium stores which can result from a net water loss or a hypertonic sodium
gain.
2.2.2 Clinical presentation
• Most patients with hypernatremia are either very young or old [13]. Signs
usually reflect central nervous system dysfunction. Elderly patients generally
have few symptoms unless sodium exceeds 160 mEq/L [13, 14].
• Brain shrinkage induced by hypernatremia can cause vascular rupture, with
cerebral bleeding, subarachnoid and permanent neurological damage. This is
counteracted by a solute movement to the brain which normalizes the brain
volume but does not correct hyperosmolality in the brain [15, 16].
• In patient with prolonged hyperosmolality, aggressive treatment with
hypotonic fluids may cause cerebral edema [17, 18].
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2.2.3 Diagnostic approach
• Net water loss accounts for a majority of cases of hypernatremia [19]. Since
sustained hypernatremia can occur only when thirst or access to water is
impaired, the groups at highest risk are patients with altered mental status,
intubated patients and elderly individuals [20].
• Hypertonic sodium gain usually results from clinical interventions or
accidental sodium loading. See Figure 3 for diagnostic approach.
2.2.4 Treatment
• The treatment of hypernatremia requires addressing the underlying cause and
correcting the prevailing hypertonicity.
• In patients who developed hypernatremia is several hours, rapid correction
improves prognosis without increasing the risk of cerebral edema. The serum
sodium can be reduced by 1 mEq/L (mmol/L) [16].
• A slower rate of correction is required in hypernatremia that lasted longer
(≥2 days) or for unknown duration [21]. ln these patients, maximal rate of
0.5 mEq/L/hr. prevents cerebral edema and seizures [22, 23]. The goal of
treatment is to reduce the serum sodium to 145 mEq/L.
• The preferred route of administering fluid is enterally however if not feasible
then fluids should be given intravenously. Hypotonic fluids such as free water,
5% dextrose, ¼ isotonic saline and ½ normal saline can be used. The more
hypotonic the infusate, the slower the infusion rate.
• Once the infusate is chosen, the freewater deficit can be calculated (see Eq. 2) [24]:





Adult Male: 60%; 50% in elderly.
Figure 3.
Diagnostic approach for hypernatremia.
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Adult Female: 50%; 45% in elderly.
• Through hospitalization, patients will have ongoing water losses which includes
insensible losses (stool, sweat, respirations) and urine free water that should be
accounted for. Insensible losses cannot bemeasured therefore can be approximated
as 30-50 ml/hr [25, 26]. Urine free water can be calculated (see Eq. 3):
Urine Free Water clearance ml=hrð Þ ¼ Urine flow rate

Urine flow rate ðUrine sodiumþUrine PotassiumÞ
Serum Sodium
(3)
• For acute or chronic hypernatremia, serum sodium should be measured every
4-6 hours and the estimated fluid replacement rate should be adjusted
accordingly.
3. Potassium homeostasis
• Patients is an important electrolyte that has been proven essential for normal
functioning of the cardiovascular system, skeletal muscle, internal organs and
nervous system.
• The intracellular proportion of K+ represents 98% of the total body K+. The
intracellular potassium concentration is approximately 140 mEq/L (mmol/L)
compared to the normal serum potassium of 3.5-5.5 mEq/L (mmol/L). This
ratio of potassium concentrations in the cells and extracellular fluid is a major
determinant of the resting membrane potential across cell membranes [27].
• An abnormal potassium level predisposes patients to serious complications
such as cardiac arrythmias, muscle weakness which could provoke sudden
cardiac arrest or respiratory failure.
3.1 Hyperkalemia
3.1.1 Introduction
• Hyperkalemia is defined as serum potassium ≥5.5 mEq/L (mmol/L) which is
commonly seen in patients with chronic kidney disease, diabetes or
cardiovascular disease. High potassium intake is rarely sufficient to result in
hyperkalemia [28].
• Based on the European Resuscitation Council Guidelines classification of
hyperkalemia based on serum potassium levels [28]:
1.Mild Hyperkalemia: - Serum Potassium 5.5-5.9 mEq/L (mmol/L)
2.Moderate Hyperkalemia: - Serum Potassium 6.0-6.4 mEq/L (mmol/L)
3.Severe Hyperkalemia: - Serum Potassium ≥6.5 mEq/L (mmol/L)
• Hyperkalemia is associated with increased mortality in patients with chronic
kidney disease and ESRD on dialysis. See Figure 4 for causes of hyperkalemia.
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3.1.2 Clinical presentation
• Hyperkalemia can manifest with neuromuscular weakness, bradycardia and
ventricular tachycardia/fibrillation. In practice however, most patients are
asymptomatic [28].
• Hyperkalemia is usually caused by increased potassium intake, decreased renal
excretion and transcellular shift in potassium. The various pathologies that could
lead to hyperkalemia can be divided based on underlying mechanism of cause:
• Pseudo-hyperkalemia refers to artificially elevated potassium which is seen in
hemolysis, severe polycythemia and prolonged tourniquet application.
3.1.3 EKG findings
• EKG changes in hyperkalemia are seen with rising serum potassium levels (see
EKG 1). Characteristically, there will be:
1.Peaked T waves, best seen in the precordial leads
2.Flattened P wave with prolonged PR interval
3.Absent P wave
4.Wide QRS and sine wave pattern
• There is a poor correlation between serum potassium levels and cardiac
manifestations reported [28, 29].
Figure 4.
Major etiologies of hyperkalemia.
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EKG 1. EKG pattern showing changes in hyperkalemia.
3.1.4 Treatment
• Whenever hyperkalemia is seen on labs, and EKG should be done. If EKG
changes are present or patient is symptomatic consistent with hyperkalemia,
then this will confirm the diagnosis.
• In practice, most patients with hyperkalemia are asymptomatic (even with
severe hyperkalemia).
• Potassium levels >6.5-7 (mmol/L) are more worrisome. Chronic hyperkalemia
is better tolerated compared to acute which is more dangerous. Chronic
hyperkalemia is seen in dialysis patients who are frequently hyperkalemic
• The acute management of hyperkalemia is the prevention or reversal of cardiac
dysrhythmias. The primary goal of chronic treatment of hyperkalemia is to
maintain serum potassium levels after acute treatment leads to reduction in
serum potassium.
• Acute management of hyperkalemia [28, 30, 31]: See Figure 5.
• IV calcium gluconate is preferred over calcium chloride because calcium
chloride causes skin irritation and extravasation which can lead to skin necrosis
or thrombophlebitis. Peripherally, 3 g IV calcium gluconate can be given over
10 min. For central access, 1 g over 10 min or slow IV push can be done.
Calcium lasts for 30-60 mins so it may need to be repeated.
• Regular insulin 10-20 units IV can be given with dextrose 25 g (when blood
glucose <250 mg/dl). In patients with renal insufficiency, short acting insulin
can be used. Insulin lasts for a few hours therefore may need to be re-dosed.
• 10-20 mg albuterol can be given in normal saline over 10 min with nebulizer.
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• Ultimately, patients will require elimination of excess potassium from the body
(Figure 6).
• Diuresis with furosemide is suggested in hypervolemic/euvolemic patients able
to produce urine. Furosemide increases urinary excretion of potassium which
can be used in both acute and chronic management. Dialysis should be
considered in patients who fail medical management, severe AKI/ESRD or
persistent EKG changes.
• Chronic Management of hyperkalemia includes maintaining serum potassium
after acute treatment [32].
Figure 5.
Steps of acute management of hyperkalemia.
Figure 6.
Continued treatment of hyperkalemia.
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• Treatment options include reviewing medication that can cause hyperkalemia,
reduction in dietary potassium intake and start medication that can increase
potassium excretion.
• Sodium zirconium cyclosilicate (Lokelma) should not be used for the acute
management of hyperkalemia due to delayed onset of action. Onset of action is
1-6 hours with duration possibly 4-12 hours. Sodium polystyrene sulfonate
(Kayexalate) has a high sodium load, and its time of onset is variable making it
a poor choice for acute management.
3.2 Hypokalemia
3.2.1 Introduction
• Hypokalemia is a common electrolyte disorder defined as potassium
<3.5 mEq/L (mmol/L) and can be life threatening if serum potassium
<2.5 mEq/L (mmol/L). A vast majority of potassium is located intracellularly
therefore hypokalemia is often due to a large total body potassium deficit [33].
• The relationship between potassium level and total body potassium deficit is
exponential; as the potassium level falls progressively lower, this represents an
exponentially larger decrease in the total body potassium deficit.
• Based on serum potassium, hypokalemia can be classified into:
1.Mild Hypokalemia: - Serum Potassium 3-3.4 mEq/L (mmol/L)
2.Moderate Hypokalemia: - Serum Potassium 2.5-2.9 mEq/L (mmol/L)
3.Severe Hypokalemia: - Serum Potassium <2.5 mEq/L (mmol/L)
• Clinical features usually occur when serum potassium<2.5 mEq/L (mmol/L)
and includes muscle pain, cramps, weakness, fatigue, constipation, syncope
and palpitations [33, 34].
3.2.2 Diagnostic approach
• Hypokalemia can be caused by excessive potassium loss, inadequate intake or a
transcellular shift of potassium.
• Inadequate potassium intake is a rare cause of hypokalemia and inmost cases,
dietary restrictions exacerbate hypokalemia due to other causes (seeFigure 7) [33].
3.2.3 EKG changes
• EKG changes associated with hypokalemia are (see EKG 2) [33]:
1.Decreased T wave amplitude
2.ST-segment depression
3.Presence of U wave (giant U waves may be mistaken for peaked T waves)
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4.Other findings include QT prolongation, ventricular extrasystoles,
ventricular arrythmias.
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3.2.4 Treatment
• Goals of treatment are to reduce further potassium loss, replenish potassium
stores, evaluate potential toxicities and treatment of the underlying cause
[33–36].
• Due to the intracellular nature of potassium deficit means that intravascular
potassium must be administered slowly, and time is required for potassium to
enter the cells. Rapid administration may cause serum levels to be elevated
even though there is a total body deficit leading to serum hyperkalemia.
• When treating hypokalemia, the goal potassium is >3.5 mEq/L (mmol/L).
Traditionally, potassium goal >4 (mmol/L) was used to reduce the risk of
arrythmias however larger studies have shown that the safest potassium level
in myocardial ischemia is 3.5-4.5 (mmol/L) with evidence of higher/lower
levels correlate with worse outcomes. In the specific case of DKA, with the
absence of renal dysfunction, target potassium is >5.3 mEq/L (mmol/L).
• Enteral potassium repletion is preferred compared to IV route. Enteral
potassium is cheaper, safer and does not irritate veins.
• Potassium chloride is the most commonly used formulation and are especially
useful with metabolic alkalosis (increases serum chloride). Slow release
formulations are suboptimal if immediate effect is desired however better
tolerated. Another formulation is potassium citrate which may be useful in
non-anion gap metabolic acidosis (the citrate will be converted into
bicarbonate, thereby improving the acidosis).
• IV potassium can be used when there is lack of gut access/function, severe
hypokalemia in need of emergent treatment or profound shock with severe
hypokalemia. The rate of administration is 10 mEq/hour through a peripheral
line or 20 mEq/hour through a central line. When IV repletion is >20 mEq/
hour then continuous cardiac monitoring is suggested.
• Magnesium should be repleted as well because failure to treat this will make it
difficult to fix hypokalemia. In patients with ongoing gastric losses, initiation
of proton pump inhibitor may minimize electrolyte derangements.
4. Calcium and phosphate balance
• Calcium circulates in different forms. Within the plasma, 40% of calcium is
bound to albumin while 15% is bound to citrate, sulfate or phosphate while
45% exists as physiologically ionized (or free) calcium. Total serum calcium is
frequently misleading since it can vary based on albumin concentration and
state of hydration [37].
• Plasma phosphorus exists as organic and inorganic forms. The inorganic forms
are completely ionized circulating in the plasma. 99% of phosphate is present
within cells.
• Only a small portion of total body calcium and phosphate is located in the
plasma and it is the ionized calcium and inorganic phosphate that is regulated
by hormones.
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• Calcium balance is regulated by the parathyroid hormone and calcitriol which
affects intestinal absorption, bone formation/ resorption and urinary excretion.
Phosphorus balance is primarily regulated by the parathyroid hormone [38].
• Most of the body’s calcium as well as phosphate exists in bone which functions
as a reservoir to maintain normal plasma ionized calcium and phosphate
concentration.
• Ionized calcium is the best measurement of biologically active calcium in
critically ill patients.
4.1 Hypocalcemia
• Common electrolyte abnormality defined as ionized calcium level < 4.4 mg/dl
or total calcium level < 8.4 mg/dl (corrected by albumin). Critically ill patients
are commonly affected. Ionized calcium <0.65 is critically low which could
cause hypotension.
4.1.1 Clinical presentation
• Clinical presentation of hypocalcemia can vary from asymptomatic to severe
symptoms. Acute hypocalcemia can present with neuromuscular irritability
(with numbness/tingling of perioral region, fingers/toes), myalgias, muscle
cramps/spasms or tetany.
• Chronic hypocalcemia (develops over years) is often asymptomatic however
still possible to cause neuromuscular irritability.
• Trousseaus sign is a hallmark sign of acute hypocalcemia in which 94% of
patients will have a positive sign [39].
• EKG changes that are seen in hypocalcemia are
1.QT segment prolongation or ST segment lengthening
2.AV conduction block
3.Acute anteroseptal injury without myocardial infarction
4.Abnormal T waves
4.1.2 Diagnostic approach
• When considering treating hypocalcemia, always confirm with ionized
calcium, magnesium and phosphate. Magnesium abnormalities can lead to
functional hypoparathyroidism.
• Calcium should also be corrected based on serum albumin.
• Various causes of hypocalcemia are
1.Medications: - Anticonvulsants (phenytoin, phenobarbital,
carbamazepine), antibiotics (rifampin, aminoglycosides, foscarnet), loop
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diuretics, chemotherapy (cisplatin, 5-fluorouracil) and drugs that inhibit
bone reabsorption (bisphosphonates, calcitonin and denosumab)
2.Severe Inflammation seen in sepsis or major buns
3.Pancreatitis (especially in hypertriglyceridemia induced pancreatitis)
4.Increased Citrate:- Seen in massive transfusion, plasmapheresis,
leukapheresis and renal replacement therapy.
5.Alkalosis
6.Chronic conditions such as hypoparathyroidism, Vit D deficiency or
osteoblastic metastasis.
7.Chronic Kidney disease (most common cause)
• Most critically ill patients have hypocalcemia and treatment is usually not
indicated. Treatment is indicated when patient is symptomatic, presence of
prolonged QT interval or severe hypocalcemia (ionized calcium<0.8) [37, 39].
• IV calcium can be used in symptomatic/severe cases or in the presence of EKG
changes. IV formulations are calcium chloride (central access) and calcium
gluconate (peripheral access). Both are equally fast however calcium chloride
can cause tissue necrosis if it extravasates.
• First, IV loading dose can be given (1 g calcium chloride or 2-3 g calcium
gluconate) followed by maintenance doses if there is an ongoing process with
smaller doses (for example calcium gluconate 1 g q1h as needed). IV calcium
increases ionized calcium in patients with hypocalcemia, but randomized trials
have not evaluated effect on clinical outcomes [40]. IV calcium can eventually
be transitioned to oral formulations.
• For mild- moderate hypocalcemia, therapy can be started with oral calcium.
Usual dose is calcium carbonate 1 g every 12 hours.
• Treatment of hypocalcemia is contraindicated in hyperphosphatemia (could
cause precipitation of calcium phosphate, calciphylaxis), ethylene glycol
poisoning (calcium promotes calcium oxalate precipitation in the brain) and
digoxin poisoning (theoretical contraindication).
4.2 Hypercalcemia
4.2.1 Introduction
• Hypercalcemia is a serum calcium>10.5 mg/dl or ionized calcium>5.6 mg/dl.
Calcium is partially bound to albumin therefore should be adjusted based
on albumin. Only ionized calcium is biologically active so, if available,
ionized calcium should be used to manage hypercalcemia among critically
ill [41].
• Hypercalcemia can be classified based on severity:
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1.Mild Hypercalcemia:- Total calcium 10.5-12 mg/dl or ionized calcium
5.6-8 mg/dl
2.Moderate Hypercalcemia:- Total calcium 12-14 mg/dl or ionized calcium
8-10 mg/dl
3.Hypercalcemic Crises:- Total calcium >14 mg/dl or ionized calcium
>10 mg/dl.
4.2.2 Clinical features
• Mild hypercalcemia may be asymptomatic however rapid increases are more
likely is be associated with symptoms than chronic hypercalcemia.
• This can present as bone pain, delirium (which could progress to stupor/
coma), paresthesia, muscle weakness, GI symptoms (abdominal pain,
pancreatitis, constipation, ileus, nausea/vomiting).
• Hypercalcemia does not commonly affect EKG or cardiac function however
short QT interval may be a common finding.
4.2.3 Diagnostic approach
• Various causes of hypercalcemia are:
1.Hyperparathyroidism (Primary and tertiary)
2.Malignancy: Approximately 80% of these cases are caused by increased
PTH-related peptide (most often squamous cell carcinoma of lung/head/
neck) which is a protein that mimics PTH. 20% of cases is due to direct
bone invasion.
3.Medications: - Vit A/D excess, increased calcium intake (milk-alkali
syndrome, chronic renal failure), teriparatide, lithium, thiazide diuretics,
TPN





• Overall, almost 90% of hypercalcemia is due to primary hyperparathyroidism
or malignancy.
• Factitious Hypercalcemia may also occur when total calcium is elevated but
ionized calcium is normal. This occurs when serum albumin or protein levels
are elevated.
16
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• Initial volume resuscitation is essential since hypercalcemia typically causes
volume depletion due to enhanced fluid excretion by the kidneys and reduced
oral intake. Plasmalyte is a good choice since it is a balanced crystalloid which
does not contain calcium. Lactated ringer contains calcium and normal saline
can cause acidosis (possibly increasing risk of renal injury) therefore both are
suboptimal compared to plasmalyte (see Figure 8).
• Mild to moderate hypercalcemia without symptoms does not require
aggressive treatment. The underlying disease should be treated, and potentially
contributing medication discontinued. Immobility may exacerbate
hypercalcemia therefore patients should be mobilized.
• In patients with severe hypercalcemia, IV fluid hydration (at least 2-4 L/day
for 1-3 days) should be given in association with bisphosphonates and
calcitonin to reduce serum calcium levels.
• Bisphosphonates block calcium release from bones causing unidirectional
uptake by the bones. These take days to work and should be started early.
Bisphosphonates should be avoided in patients with increased calcium intake
(milk-alkali syndrome. The main side effect is renal failure however the most
common is flu-like syndrome which can be treated symptomatically. Various
options are pamidronate 60-90 mg IV or zoledronic acid 4 mg IV [41, 42].
• Calcitonin is an excellent agent to control severe symptomatic hypocalcemia
while waiting for bisphosphonates to take effect. These work by reducing bone
calcium reabsorption and cause a temporary reduction in calcium. Calcitonin
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subcutaneously every 12 hours for 24 hours; effect of calcitonin is short lived,
and tolerance typically develops within 2 days [43].
• In patients who bisphosphonates and calcitonin are ineffective, denosumab
(monoclonal antibody that inhibits osteoclast formation and bone resorption)
can be considered.
• Loop diuretics can be used once volume status normalizes to enhance calcium
excretion and to avoid volume overload. They may have to be started earlier if
patient has a history of congestive heart failure or kidney disease.
Glucocorticoids can be given in patients with granulomatous disease, Vit D
overdose or malignancy to inhibit conversion of Vit D to calcitriol.
• In renal failure, dialysis with low calcium bath is an option.
4.3 Hyperphosphatemia
• Hyperphosphatemia is defined as serum phosphate >4.5 mg/dl in adults.
• Hyperphosphatemia is itself, asymptomatic however can indirectly cause
symptoms by causing symptomatic hypocalcemia (by binding to calcium) or
calciphylaxis (precipitation of calcium phosphate in tissues which can manifest
as skin ulceration).
• Sustained hyperphosphatemia generally occurs in renal failure since normally
the kidneys are efficient in phosphate excretion. Possible inciting events are
[44]
1.Tissue necrosis: Tumor lysis syndrome, rhabdomyolysis, hemolysis,
fulminant hepatitis, severe hyperthermia
2.Endocrinopathy: Hypoparathyroidism, hypothyroidism/
hyperthyroidism, adrenal insufficiency, acromegaly
3.Medications: Exogenous phosphate intake (phosphate containing
laxatives/enemas, TPN), Vit D toxicity, bisphosphonates, fosphenytoin
• False elevation of phosphate can be seen in hyperlipidemia,
hyperbilirubinemia, hyperglobulinemia (multiple myeloma) or a hemolyzed
specimen.
• Calcium phosphate product (see Eq. 4) can predict the risk of calciphylaxis and
is more important than the phosphate level alone. Calcium-phosphate
product>70 causes an increased risk of calciphylaxis.
Calcium Phosphate Product ¼ Serum Calcium x Serum Phosphate (4)
• Acute treatment of hyperphosphatemia (see Figure 9) includes treating
inciting event, phosphate restricted diet, fluid resuscitation and forced diuresis
(acetazolamide+  furosemide) or dialysis [44].
18
Mineral Deficiencies - Electrolyte Disturbances, Genes, Diet and Disease Interface
• If patient has persistent renal failure, can start oral phosphate binder. Calcium
acetate can be useful in patients with concomitant hypocalcemia and should be
avoided in patients with hypercalcemia, Vitamin D toxicity and Ca-Phos
product>66. Sevelamer is a nonabsorbable resin that is preferred for patients
on dialysis [44].
4.4 Hypophosphatemia
• Hypophosphatemia is defined as serum phosphate <2.5 mg/dl.
• Patients with hypophosphatemia can present with paresthesia, tremors,
seizures, impaired heart contractility, arrythmias, muscle weakness (including
the diaphragm). Usually, symptoms occur at levels <1-2.5 mg/dl. Most cases of
mild (or even moderate) hypophosphatemia are asymptomatic.
• Causes of hypophosphatemia are [45]:
1.Shifting phosphate into cells: Diabetic ketoacidosis, refeeding syndrome,
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2.Reduced GI uptake: Inadequate oral intake, chronic diarrhea, drugs
(chronic use of antacids containing calcium, magnesium or aluminum).
3.Increased Renal losses: Diuretics (loop diuretics, acetazolamide,
thiazides), osmotic diuresis, auto-diuresis (post-ATN, iatrogenic volume
overload), CRRT, hyperparathyroidism, other medications
(aminoglycosides, IV iron, tenofovir, chemotherapeutic agents).
4.Multifactorial: Alcoholism, Vitamin D deficiency, critical illness (sepsis,
trauma, major surgery, burns).
5.Potential causes of pseudo-hypophosphatemia are hyperbilirubinemia,
mannitol, paraproteins and acute leukemia.
• Generally, hypophosphatemia can be determined by history and review of
labs/medication. Fractional excretion of phosphate can be helpful in cases
when cause is unclear. Fractional excretion of phosphate should be <5% as a
normal response to hypophosphatemia however >5% can be seen in renal
phosphate wasting [45, 46].
• IV phosphate can be given for severe hypophosphatemia, symptomatic, or in
patients with lack of enteral access or malabsorption. These should be infused
slowly since rapid infusion can lead to transient hyperphosphatemia (leading
to hypocalcemia). Either potassium or sodium phosphate can be used.
• Oral phosphate can be given however tends to cause diarrhea. It is available as
Phos-NAKpackets (which contains 8mMphosphate, 7mEq potassiumand 7mEq
sodium), oral sodium phosphate liquid and oral potassium phosphate liquid [47].
◦ Phosphate ≤1.5 mg/dl:- Orally, 16 mM phosphate every 6 hours.
Intravenously, initial dose can be 30 mM infused over 4 hours
◦ Phosphate >1.5 mg/dl:- Orally, 8 mM phosphate every 8 hours.
Intravenously, initial dose of 15 mM phosphate can be infused over
2 hours.
• Patients with active refeeding syndrome and morbid obesity, can consider
using higher doses than indicated based on phosphate levels.
5. Magnesium homeostasis
• Magnesium is the 4th most abundant cation in the body. Magnesium
homeostasis needs to be tightly regulated and thus facilitated by intestinal
absorption and renal excretion. Magnesium plays an essential role in bone
formation, neuromuscular stability and muscle contraction.
5.1 Hypomagnesemia
• Magnesium <1.8 mg/dl is defined as hypomagnesemia. Reported prevalence of
hypomagnesemia ranges from 2.5-15% in the general population however
higher in the ICU setting.
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• Most patients are asymptomatic until concentration is <1.2 mg/dl however
presentation can overlap with other abnormalities. Patients can present with
nausea/vomiting, loss of appetite, neuromuscular irritability, tremors/tetany,
hypocalcemia, hypokalemia, seizures, psychosis and arrythmias [48].
• Hypomagnesemia induced EKG changes include:
1.Flattened T wave and U waves
2.Prolonged QT interval and widened QRS complex
3.Prolonged QT interval
• Causes of hypomagnesemia are:
1.Medications: - Diuretics (except potassium sparing diuretics),
antibiotics such as aminoglycoside, amphotericin and pentamidine,
cyclosporine and tacrolimus, platinum based chemotherapy and proton
pump inhibitors
2.Hypercalcemia, hyperphosphatemia, metabolic acidosis
3.Renal disease: - Post-ATN diuresis, osmotic diuresis, renal tubular acidosis
4.GI Losses: - Malabsorption, diarrhea/vomiting, pancreatitis
5.Chronic alcoholism, diabetes, large volume transfusion of citrated blood
products, sepsis
• Magnesium repletion is generally safe except for myasthenia gravis (due to
increased risk of muscle weakness) and renal failure.
• For patients with mild hypomagnesemia (1.5-2 mg/dl), oral magnesium can be
used. Oral formulations are magnesium oxide 400 mg twice a day or
magnesium hydroxide milk of magnesia) 15 ml once daily. If unable to take PO
medication, 2 g of IV magnesium sulphate can be given.
• For moderate hypomagnesemia (1.2-1.5 mg/dl), intermittent infusions of 2-4 g
magnesium sulphate IV can be given. To improve intracellular absorption, the
dose can be infused for a longer period of time.
• For severe hypomagnesemia (<1.2 mg/dl), multiple doses of IV magnesium
can be given or a continuous infusion of IV magnesium (4-8 g IV magnesium
sulphate over 24 hours) (see Figure 10).
• 1 g magnesium sulphate is equivalent to 100 mg of elemental magnesium.
• In Torsade de Pointes or seizures secondary to hypomagnesemia, patients can
be loaded with 2 g magnesium sulphate over 5-15 min followed by 2 g
additionally over 30-60 min. These are followed by a continuous infusion of
magnesium sulphate 1 g/hour. If the magnesium level is 5-7 mg/dl, the infusion
should be reduced by 50%. If magnesium is >7 mg/dl then the infusion should
be stopped.
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5.2 Hypermagnesemia
• Magnesium>2.6 mg/dl is defined as hypermagnesemia. Patients with serum
magnesium<4.8 mg/dl are usually asymptomatic, deep tendon reflexes may be
diminished with serum magnesium>6.1 mg/dl and absent when >12 mg/dl [48].
• Patients can present with lethargy, confusion, nausea, vomiting, bradycardia.
In severe cases, muscle weakness, respiratory distress, apnea, heart block,
severe bradycardia, delirium and coma [48].
• EKG will show widened QRS complex with peaked T waves. Heart block can
also be seen.
• Renal failure is required in addition to another source of magnesium to cause
persistent hypermagnesemia. Concomitant causes of hypermagnesemia are:
1.Exogenous magnesium:- Magnesium infusion for pre-eclampsia,
magnesium containing antacids and magnesium containing
laxatives/enema
2.Endogenous magnesium from cellular lysis:- Rhabdomyolysis, hemolysis,
tumor lysis syndrome and crush injury, severe burns.
Figure 10.
Treatment of severe symptomatic hypomagnesemia.
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• In most cases of hypermagnesemia, discontinuing magnesium containing
drugs or supplements or volume replacement can sufficiently treat it [48].
• In patients with moderate hypermagnesemia (3.6-10 mg/dl or no cardiac/
respiratory symptoms), the underlying cause should be treated. Furosemide
can be used to enhance magnesium excretion.
• In patients with severe hypermagnesemia (causing cardiac/respiratory
symptoms), IV calcium is required to stabilize the myocardium (2 g of calcium
gluconate IV over 5-10 min followed by a continuous infusion in severe cases).
In patients who are non-oliguric, furosemide with IV fluids can be used for
elimination of magnesium. In patients who are oliguric, emergent dialysis is
required.
6. Common conditions in the ICU
6.1 Massive transfusion protocol
• Massive transfusion protocol should be used in critically ill bleeding patients
anticipated to require massive transfusion.
• Two common electrolytes that occur during MTP are hypocalcemia and
hyperkalemia.
• Hypocalcemia is caused by the presence of the anticoagulant citrate (each bag
on pRBC contains 3 g citrate). Normally, this amount can be rapidly cleared by
the liver however in critically ill patients receiving multiple units, the process
of liver elimination is compromised. Citrate accumulates in the blood where it
binds to circulating ionized calcium thereby causing hypocalcemia [49].
• Bedside measurement of calcium can be used to guide calcium management.
When administering MTP (around 6 units pRBC), it is reasonable to
administer 3 g calcium gluconate.
• Hyperkalemia has been shown to be a risk when patients are transfused
>7 units of pRBC [50]. This can be exacerbated in patients with renal failure,
effective circulating volume depletion or more commonly hypoaldosteronism.
There have been studies suggesting there may be a link between incidence of
hyperkalemia and the use of washed or unwashed blood products and length of
RBC storage [51].
Abbreviations
ICU Intensive Care Unit
RAAS Renin Angiotensin Aldosterone System
mEQ/L milli-equivalent per liter
mMol/L milli-mole per liter
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Mosmol Milli-osmols
EABV effective arterial blood volume
SIADH syndrome of inappropriate anti-diuretic hormone
Mcg microgram
SubQ subcutaneous
D5W 5% dextrose solution in water
MRI magnetic resonance imaging
DWI diffusion weighted imaging
EKG electrocardiogram
AKI acute kidney injury





Vit D Vitamin D
TPN total parenteral nutrition
PTH parathyroid hormone
GI gastrointestinal
ATN acute tubular necrosis
CRRT continuous renal replacement therapy
PO per-oral
MTP massive transfusion protocol
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